Treatment of generalized dystonia
- PMID: 21455718
- DOI: 10.1007/s11940-011-0122-0
Treatment of generalized dystonia
Abstract
The armamentarium for clinicians treating patients with generalized dystonia, previously restricted to only a few oral medications that often caused intolerable side effects, has been radically expanded in the past decade with the widespread application of deep brain stimulation (DBS). With DBS, patients who in the past would have been restricted to a life of severe motor disability from a young age can now lead lives with only minimal symptoms. Although DBS should therefore be considered as a treatment option for any patient with severe, medically refractory dystonia, important questions remain about patient selection, including what factors predict which patients will benefit from DBS, and when in the course of disease DBS should be performed. Reports show that patients with primary dystonia respond better than those with secondary dystonia, and limb and axial muscles may improve more than cranial dystonia. Some studies also suggest that shorter duration of disease may be associated with better outcomes. However, it is important to note that even among those thought to respond best to DBS, i.e. patients with primary generalized dystonia, there is a subset that will have significant and sustained clinical benefit with oral medications. It is therefore important that adequate trials of oral medications be attempted prior to referral for surgery. On the other hand, once it is clear that medical therapies are not providing significant benefit or are not well tolerated, children with disabling generalized primary dystonia should be referred quickly for DBS. The dramatic clinical improvement that can be seen with DBS can restore normal or near-normal functioning and avoid the physical and emotional costs of an extended period of decreased physical and social functioning. In general, a levodopa trial should always be considered as the first treatment at the time of presentation of any patient with childhood-onset limb dystonia, in order to exclude dopa-responsive dystonia. Once a diagnosis of primary generalized dystonia is established, we typically initiate treatment with trihexyphenidyl, titrating slowly up to a high dose. We then frequently add baclofen as a second agent. If clinical improvement at that point is inadequate and the dystonia is causing significant functional impairment, we then consider referral for DBS.
Similar articles
-
Deep brain stimulation in children and young adults with secondary dystonia: the Children's Hospital Los Angeles experience.Neurosurg Focus. 2013 Nov;35(5):E7. doi: 10.3171/2013.8.FOCUS13300. Neurosurg Focus. 2013. PMID: 24175867
-
Experience of pallidal deep brain stimulation in dystonia at a tertiary care centre in India: An initial experience.Neurol India. 2017 Nov-Dec;65(6):1322-1329. doi: 10.4103/0028-3886.217957. Neurol India. 2017. PMID: 29133709
-
Proportion of life lived with dystonia inversely correlates with response to pallidal deep brain stimulation in both primary and secondary childhood dystonia.Dev Med Child Neurol. 2013 Jun;55(6):567-74. doi: 10.1111/dmcn.12117. Epub 2013 Mar 1. Dev Med Child Neurol. 2013. PMID: 23452222
-
[Deep brain stimulation for Parkinson's disease and dystonia].Brain Nerve. 2009 Apr;61(4):473-83. Brain Nerve. 2009. PMID: 19378817 Review. Japanese.
-
Inclusion and exclusion criteria for DBS in dystonia.Mov Disord. 2011 Jun;26 Suppl 1(Suppl 1):S5-16. doi: 10.1002/mds.23482. Mov Disord. 2011. PMID: 21692112 Free PMC article. Review.
Cited by
-
Revised consensus statement on the preventive and symptomatic care of patients with leukodystrophies.Mol Genet Metab. 2017 Sep;122(1-2):18-32. doi: 10.1016/j.ymgme.2017.08.006. Epub 2017 Aug 20. Mol Genet Metab. 2017. PMID: 28863857 Free PMC article.
-
Lesch-Nyhan Syndrome: Models, Theories, and Therapies.Mol Syndromol. 2016 Nov;7(6):302-311. doi: 10.1159/000449296. Epub 2016 Sep 24. Mol Syndromol. 2016. PMID: 27920633 Free PMC article. Review.
-
Complex care of individuals with multiple sulfatase deficiency: Clinical cases and consensus statement.Mol Genet Metab. 2018 Mar;123(3):337-346. doi: 10.1016/j.ymgme.2018.01.005. Epub 2018 Jan 31. Mol Genet Metab. 2018. PMID: 29397290 Free PMC article.
-
Generalized dystonia unraveled: Molecular mechanisms, diagnostic strategies, and treatment paradigms.Neurol Sci. 2025 Aug 22. doi: 10.1007/s10072-025-08404-3. Online ahead of print. Neurol Sci. 2025. PMID: 40841848 Review.
-
Lessons Learned from Open-label Deep Brain Stimulation for Tourette Syndrome: Eight Cases over 7 Years.Tremor Other Hyperkinet Mov (N Y). 2013 Nov 1;3:tre-03-170-4428-1. doi: 10.7916/D8M32TGM. eCollection 2013. Tremor Other Hyperkinet Mov (N Y). 2013. PMID: 24255802 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Miscellaneous